Indivior PLC (INDV) Stock Analysis: Exploring a 25% Upside Potential with Strong Buy RatingsIndivior PLC (INDV) is making waves in the healthcare sector, specifically within the specialty and generic drug manufacturing industry. This suggests that the market expects stable earnings growth, presenting an attractive valuation for potential investors. The target price range of $27.00 to $34.00 implies an average target of $29.17, translating to a potential upside of 25.34%. This significant upside potential could be a compelling factor for investors seeking growth opportunities in the healthcare sector. As the company continues to address critical health challenges, it remains a strong contender for those looking to capitalize on its potential upside and robust analyst support.